JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
Authors
Keywords
-
Journal
BLOOD
Volume 123, Issue 10, Pages 1544-1551
Publisher
American Society of Hematology
Online
2013-12-24
DOI
10.1182/blood-2013-11-539098
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms
- (2013) E. Rumi et al. BLOOD
- JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone
- (2012) A. L. Godfrey et al. BLOOD
- Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
- (2012) T. Barbui et al. BLOOD
- A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment
- (2012) F. Passamonti et al. BLOOD
- Calreticulin signaling in health and disease
- (2012) Wen-An Wang et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study
- (2012) Malin Hultcrantz et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
- (2011) F. Passamonti et al. BLOOD
- Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
- (2011) A. Carobbio et al. BLOOD
- Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms
- (2011) D. Pietra et al. HAEMATOLOGICA
- Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic and Epigenetic Complexity in Myeloproliferative Neoplasms
- (2011) N. C. P. Cross Hematology-American Society of Hematology Education Program
- Distinct Clinical Phenotypes Associated with JAK2V617F Reflect Differential STAT1 Signaling
- (2010) Edwin Chen et al. CANCER CELL
- A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
- (2010) F Passamonti et al. LEUKEMIA
- Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis
- (2009) L. Malcovati et al. BLOOD
- Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
- (2007) R. Tiedt et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now